Description
AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC50 values of 0.005 µM and 0.023 µM, respectively. AZ1495 has IRAK4 inhibition with a Kd value of 0.0007 µM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL)[1]